Novavax Inc
NVAX
Novavax Inc News & Analysis
stocks
Vaccine rollout and herd immunity to end the pandemic
Covid will create a $52bn vaccine and treatment market and usher in immunity by 2023, writes Morningstar's Karen Andersen.
markets
What a Covid-19 vaccine means for investors
Three new vaccines for coronavirus look poised for emergency use authorisation in the US this autumn. What does that mean for investors?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,424.10 | 13.30 | -0.14% |
| CAC 40 | 8,715.67 | 0.74 | 0.01% |
| DAX 40 | 26,339.59 | 20.14 | 0.08% |
| Dow JONES (US) | 54,005.94 | 30.99 | -0.06% |
| FTSE 100 | 10,853.07 | 48.02 | -0.44% |
| HKSE | 25,937.49 | 269.46 | 1.05% |
| NASDAQ | 26,707.30 | 16.69 | 0.06% |
| Nikkei 225 | 66,970.22 | 1,363.51 | 2.08% |
| NZX 50 Index | 13,888.24 | 64.11 | 0.46% |
| S&P 500 | 7,770.39 | 12.75 | 0.16% |
| S&P/ASX 200 | 9,232.60 | 17.00 | -0.18% |
| SSE Composite Index | 3,966.59 | 26.56 | 0.67% |